133 related articles for article (PubMed ID: 24121042)
1. Role of TNFRSF1B polymorphisms in the response of Crohn's disease patients to infliximab.
Medrano LM; Taxonera C; Márquez A; Barreiro-de Acosta M; Gómez-García M; González-Artacho C; Pérez-Calle JL; Bermejo F; Lopez-Sanromán A; Martín Arranz MD; Gisbert JP; Mendoza JL; Martín J; Urcelay E; Núñez C
Hum Immunol; 2014 Jan; 75(1):71-5. PubMed ID: 24121042
[TBL] [Abstract][Full Text] [Related]
2. The tumor necrosis factor receptor superfamily member 1B polymorphisms predict response to anti-TNF therapy in patients with autoimmune disease: A meta-analysis.
Chen W; Xu H; Wang X; Gu J; Xiong H; Shi Y
Int Immunopharmacol; 2015 Sep; 28(1):146-53. PubMed ID: 26071216
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease.
Steenholdt C; Enevold C; Ainsworth MA; Brynskov J; Thomsen OØ; Bendtzen K
Aliment Pharmacol Ther; 2012 Oct; 36(7):650-9. PubMed ID: 22860894
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms of the TNF gene and the TNF receptor superfamily member 1B gene are associated with susceptibility to ulcerative colitis and Crohn's disease, respectively.
Sashio H; Tamura K; Ito R; Yamamoto Y; Bamba H; Kosaka T; Fukui S; Sawada K; Fukuda Y; Tamura K; Satomi M; Shimoyama T; Furuyama J
Immunogenetics; 2002 Mar; 53(12):1020-7. PubMed ID: 11904678
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphisms in tumour necrosis factor receptors (
Qasem A; Ramesh S; Naser SA
BMJ Open Gastroenterol; 2019; 6(1):e000246. PubMed ID: 30815272
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms of tumour necrosis factor receptor superfamily 1A and 1B affect responses to infliximab in Japanese patients with Crohn's disease.
Matsukura H; Ikeda S; Yoshimura N; Takazoe M; Muramatsu M
Aliment Pharmacol Ther; 2008 May; 27(9):765-70. PubMed ID: 18248655
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor receptor gene polymorphisms in Crohn's disease: association with clinical phenotypes.
Waschke KA; Villani AC; Vermeire S; Dufresne L; Chen TC; Bitton A; Cohen A; Thomson AB; Wild GE
Am J Gastroenterol; 2005 May; 100(5):1126-33. PubMed ID: 15842589
[TBL] [Abstract][Full Text] [Related]
8. Association of TNF-α, TNFRSF1A and TNFRSF1B gene polymorphisms with the risk of sporadic breast cancer in northeast Chinese Han women.
Xu F; Zhou G; Han S; Yuan W; Chen S; Fu Z; Li D; Zhang H; Li D; Pang D
PLoS One; 2014; 9(7):e101138. PubMed ID: 25010932
[TBL] [Abstract][Full Text] [Related]
9. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab.
Pierik M; Vermeire S; Steen KV; Joossens S; Claessens G; Vlietinck R; Rutgeerts P
Aliment Pharmacol Ther; 2004 Aug; 20(3):303-10. PubMed ID: 15274667
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents.
Kestens C; van Oijen MG; Mulder CL; van Bodegraven AA; Dijkstra G; de Jong D; Ponsioen C; van Tuyl BA; Siersema PD; Fidder HH; Oldenburg B;
Clin Gastroenterol Hepatol; 2013 Jul; 11(7):826-31. PubMed ID: 23376000
[TBL] [Abstract][Full Text] [Related]
11. Genetic Polymorphisms of IL-17F and TRAF3IP2 Could Be Predictive Factors of the Long-Term Effect of Infliximab against Crohn's Disease.
Urabe S; Isomoto H; Ishida T; Maeda K; Inamine T; Kondo S; Higuchi N; Sato K; Uehara R; Yajima H; Machida H; Chen CC; Fukuda Y; Takeshima F; Nakao K; Tsukamoto K
Biomed Res Int; 2015; 2015():416838. PubMed ID: 26558270
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population.
Vasilopoulos Y; Manolika M; Zafiriou E; Sarafidou T; Bagiatis V; Krüger-Krasagaki S; Tosca A; Patsatsi A; Sotiriadis D; Mamuris Z; Roussaki-Schulze A
Mol Diagn Ther; 2012 Feb; 16(1):29-34. PubMed ID: 22111980
[TBL] [Abstract][Full Text] [Related]
13. Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease.
Steenholdt C
Dan Med J; 2013 Apr; 60(4):B4616. PubMed ID: 23651723
[TBL] [Abstract][Full Text] [Related]
14. Infliximab-induced psoriasis and psoriasiform skin lesions in pediatric Crohn disease and a potential association with IL-23 receptor polymorphisms.
Sherlock ME; Walters T; Tabbers MM; Frost K; Zachos M; Muise A; Pope E; Griffiths AM
J Pediatr Gastroenterol Nutr; 2013 May; 56(5):512-8. PubMed ID: 23274341
[TBL] [Abstract][Full Text] [Related]
15. Association between tumor necrosis factor-alpha and Fc-gamma receptor polymorphisms with infliximab in Crohn's disease.
Tomita K; Chiba T; Sugai T; Habano W
Hepatogastroenterology; 2010; 57(99-100):535-9. PubMed ID: 20698223
[TBL] [Abstract][Full Text] [Related]
16. Role of TNFRSF1A and TNFRSF1B polymorphisms in susceptibility, severity, and therapeutic efficacy of etanercept in human leukocyte antigen-B27-positive Chinese Han patients with ankylosing spondylitis.
Xing-Rong W; Sheng-Qian X; Wen L; Shan Q; Fa-Ming P; Jian-Hua X
Medicine (Baltimore); 2018 Aug; 97(31):e11677. PubMed ID: 30075559
[TBL] [Abstract][Full Text] [Related]
17. Concomitant use of enteral nutrition therapy is associated with sustained response to infliximab in patients with Crohn's disease.
Sazuka S; Katsuno T; Nakagawa T; Saito M; Saito K; Matsumura T; Arai M; Sato T; Yokosuka O
Eur J Clin Nutr; 2012 Nov; 66(11):1219-23. PubMed ID: 23010687
[TBL] [Abstract][Full Text] [Related]
18. Genetic predictors of long-term response and trough levels of infliximab in crohn's disease.
Salvador-Martín S; López-Cauce B; Nuñez O; Laserna-Mendieta EJ; García MI; Lobato E; Abarca-Zabalía J; Sanjurjo-Saez M; Lucendo AJ; Marín-Jiménez I; Menchén LA; López-Fernández LA
Pharmacol Res; 2019 Nov; 149():104478. PubMed ID: 31605784
[TBL] [Abstract][Full Text] [Related]
19. Cigarette smoking, STAT4 and TNFRSF1B polymorphisms, and systemic lupus erythematosus in a Japanese population.
Kiyohara C; Washio M; Horiuchi T; Tada Y; Asami T; Ide S; Atsumi T; Kobashi G; Takahashi H;
J Rheumatol; 2009 Oct; 36(10):2195-203. PubMed ID: 19684152
[TBL] [Abstract][Full Text] [Related]
20. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism.
Louis E; Vermeire S; Rutgeerts P; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Malaise M; Belaiche J
Scand J Gastroenterol; 2002 Jul; 37(7):818-24. PubMed ID: 12190096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
